Efficacy of intrathecal injection of methylprednisolone in treatment of multiple sclerosis and its effect on T-lymphocyte subsets
DONG Yan-ling
LI-Lv-li
LI Yao-xuan
LIANG Hao
TENG Xiao-ming
Abstract：Objective To observe the efficacy of intrathecal injection of methylprednisolone ( MPS) in treatment of multiple sclerosis ( MS) and its effect on T-lymphocyte subsets .Methods Eighty patients with acute MS were divided into the MPS intrathecal injection group (35 cases) and MPS impact group (45 cases).The two groups were treated with con-ventional neurotrophic drugs , and then were treated with intrathecal injection of MPS and conventional intravenous impact therapy .Flow cytometry was used to evaluate the levels of T-lymphocyte subsets and peripheral blood of the two groups be-fore and after treatment for 2 weeks.Then we evaluated the neurological scores by using Kurtzke expanded disability status scale (EDSS).Results After treatment for 5 days, the ΔEDSS in the MPS intrathecal injection group was higher than that in the MPS impact group (t=17.516, P<0.05), but no difference was found between the two groups after treatment for 10 and 15 days (all P>0.05).The CD4+decreased and CD8+increased in cerebrospinal fluid (CSF), and the CD4+increased and the CD 4+/CD8+decreased in the peripheral blood of the two groups after treatment as compared with those be -fore treatment.The difference in the indexes of T-lymphocyte subsets was not statistical significant between the two groups after treatment (all P>0.05).Conclusions Intrathecal injection of MPS in treatment of MS works faster and the neuro-logical function improves better as compared with the MPS impact therapy .With the remission of the disease , there are dif-ferent degrees of improvement in the T-lymphocyte subsets .
Keywords：multiple sclerosismethylprednisoloneintrathecal injectionT-lymphocyte subsets
Publication Date：2014-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：3( 18-20 )